In the recent years numerous clinical trials have demonstrated the efficacy of anti-PD-1 and PD-L1 antibodies leading to FDA approval of nivolumab for patients with advanced melanoma, renal cell carcinoma (RCC), and non-small cell carcinoma (NSCLC) alongside pembrolizumab for treatment of advanced melanoma and non-small cell carcinoma NSCLC, and atezolizumab for urothelial carcinoma (UC) [1–6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.